Buyukbayram M, Hannarici Z, Yilmaz A, Turhan A, Caglar A, Coban Esdur P
Lung Cancer Manag. 2024; 13(1):LMT66.
PMID: 38818368
PMC: 11137794.
DOI: 10.2217/lmt-2023-0014.
Paz Del Socorro T, Oka K, Boulard O, Takahashi M, Poulin L, Hayashi A
Gut Microbes. 2024; 16(1):2315631.
PMID: 38385162
PMC: 10885180.
DOI: 10.1080/19490976.2024.2315631.
Zhao M, Shao T, Shao H, Zhou C, Tang W
BMC Cancer. 2024; 24(1):186.
PMID: 38331773
PMC: 10851546.
DOI: 10.1186/s12885-024-11916-4.
He J, Luan T, Zhao G, Yang Y
J Inflamm Res. 2023; 16:5309-5326.
PMID: 38026246
PMC: 10658954.
DOI: 10.2147/JIR.S436431.
Yolchuyeva S, Giacomazzi E, Tonneau M, Lamaze F, Orain M, Coulombe F
Sci Rep. 2023; 13(1):11065.
PMID: 37422576
PMC: 10329671.
DOI: 10.1038/s41598-023-38076-y.
The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment.
Pontis F, Roz L, Fortunato O, Bertolini G
Front Oncol. 2023; 13:1116783.
PMID: 37207158
PMC: 10189117.
DOI: 10.3389/fonc.2023.1116783.
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J
Front Immunol. 2022; 13:974581.
PMID: 36159860
PMC: 9494286.
DOI: 10.3389/fimmu.2022.974581.
Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Beca J, Walsh S, Raza K, Hubay S, Robinson A, Mow E
BMC Cancer. 2021; 21(1):1162.
PMID: 34715804
PMC: 8556902.
DOI: 10.1186/s12885-021-08746-z.
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C
Mol Cancer Ther. 2021; 20(9):1723-1734.
PMID: 34224361
PMC: 9398146.
DOI: 10.1158/1535-7163.MCT-20-0902.
Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.
Guo W, Zhang C, Qiao T, Zhao J, Shi C
Front Oncol. 2021; 11:673199.
PMID: 33996603
PMC: 8117211.
DOI: 10.3389/fonc.2021.673199.
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
Fan T, Liu Y, Liu H, Wang L, Tian H, Zheng Y
Cancer Immunol Immunother. 2021; 70(12):3651-3667.
PMID: 33977344
PMC: 10992915.
DOI: 10.1007/s00262-021-02944-1.
Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl K
J Immunother Cancer. 2021; 9(3).
PMID: 33789880
PMC: 8016096.
DOI: 10.1136/jitc-2020-002262.
Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.
Zhang X, Xie W, Wang Z, Song S, Qin Y, Zhang F
Ann Transl Med. 2020; 8(9):589.
PMID: 32566616
PMC: 7290544.
DOI: 10.21037/atm-20-2548.
Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?.
Freidlin B, Korn E
J Clin Oncol. 2019; 37(35):3455-3459.
PMID: 31647681
PMC: 7001779.
DOI: 10.1200/JCO.19.01681.
Liquid biopsy for lung cancer immunotherapy.
Cai L, Wang J
Oncol Lett. 2019; 17(6):4751-4760.
PMID: 31186680
PMC: 6507432.
DOI: 10.3892/ol.2019.10166.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L
Ann Oncol. 2019; 30(8):1321-1328.
PMID: 31125062
PMC: 7389252.
DOI: 10.1093/annonc/mdz167.
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.
Pan Y, Fei Q, Xiong P, Yang J, Zhang Z, Lin X
Oncoimmunology. 2019; 8(5):e1581529.
PMID: 31069140
PMC: 6492971.
DOI: 10.1080/2162402X.2019.1581529.
The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.
Fruhwirth G, Kneilling M, de Vries I, Weigelin B, Srinivas M, Aarntzen E
Mol Imaging Biol. 2018; 20(5):696-704.
PMID: 30030697
PMC: 6153672.
DOI: 10.1007/s11307-018-1254-3.
Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.
Tiu A, Potdar R, Djibo D, Masab M, Dourado C
Med Oncol. 2018; 35(7):109.
PMID: 29915891
DOI: 10.1007/s12032-018-1171-y.
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Mohamad O, De Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E
Oncoimmunology. 2018; 7(7):e1440168.
PMID: 29900043
PMC: 5993514.
DOI: 10.1080/2162402X.2018.1440168.
